NorthWest Biotherapeutics Inc (NWBO)

[abeta]

George - just gotta uncork this

Poly-ICLC links at the bottom and I jiggled this all around to
suit my needs

Whats the point?
Poly-ICLC and DCVax-Direct is a dream come true

Remember - NWBO (poly off-label) just has to prove SAFETY not efficacy.
(so we don't have to wait for trial completions)

Poly-ICLC (Hiltonol) is under development for
(George - we've seen this before)

solid tumors,
metastatic pancreatic cancer,
non-small cell lung cancer,
MMR-p colorectal cancer,
colon cancer,
bladder cancer,
kidney cancer and
colorectal cancer,
pancreatic ductal adenocarcinoma,
melanoma,
squamous head and neck cancer,
sarcoma,
malignant pleural mesothelioma,
lymphomas including cutaneous T-cell lymphoma,
B-cell lymphoma,
merkel cell carcinoma,
metastatic adenocarcinoma of pancreas,
prostate cancer,
HIV-1 infection,
epithelial ovarian cancer,
fallopian tube cancer and primary peritoneal cancer (first line therapy),
recurrent or metastatic breast cancer,
low-grade glioma
Coronavirus disease 2019 (COVID-19)
human papillomavirus (HPV)-associated HNSCC,

Poly-ICLC (Hiltonol) - Brother of DCVax-Direct

The drug candidate is a synthetic complex of
carboxymethylcellulose,
polyinosinic-polycytidylic acid
and poly-L-lysine double-stranded RNA.

Poly-ICLC is a viral mimic and broad activator of innate immunity.

Poly ICLC may stimulate the release of cytotoxic cytokines and by inducing interferon-gamma production,
may increase the tumoricidal activities of various immunohematopoietic cells.
It activates the oligoadenylate synthetase (OAS) and the p68 protein kinase.
It is also acts as TLR3 agonist.

The drug was also under development for the treatment of
brain tumor,
anaplastic astrocytoma,
anaplastic oligoastrocytoma,
oligodendroglioma,
glioblastoma multiforme,
poxviridae infections,
west nile virus infections,
japanese encephalitis,
dengue fever,
yellow fever,
st louis encephalitis,
murray valley,
orthopox virus infections,
banzai viruses,
smallpox,
severe acute respiratory syndrome (SARS),
acute myeloid leukemia,
myelodysplastic syndrome,
chronic myelomonocytic leukemia (CMML)
and influenza.

https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-breast-cancer-likelihood-of-approval/?cf-view